ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

janssen-cilag international n.v.   - decitabine - leukemia, myeloid - antineoplastic agents - treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (aml), according to the world health organization (who) classification, who are not candidates for standard induction chemotherapy.

মাল্যাশিয়া - ইংরেজি - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

healol pharmaceuticals sdn. bhd. - decitabine -

মাল্যাশিয়া - ইংরেজি - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - decitabine -

কানাডা - ইংরেজি - Health Canada

pendopharm division of pharmascience inc - decitabine - powder - 50mg - decitabine 50mg - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

otsuka pharmaceutical co ltd - decitabine; cedazuridine - tablet - 35mg; 100mg - decitabine 35mg; cedazuridine 100mg - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

otsuka pharmaceutical co ltd - decitabine - powder - 50mg - decitabine 50mg - antineoplastic agents

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - decitabine - powder for solution for infusion - 50mg

ইউরোপীয় ইউনিয়ন - ইংরেজি - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemia, myeloid - antineoplastic agents - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

ইস্রায়েল - ইংরেজি - Ministry of Health

j-c health care ltd - decitabine - powder for concentrate for solution for infusion - decitabine 50 mg/vial - decitabine - - dacogen is indicated for treatment of patients with myelodysplastic syndromes (mds) including prevviously treated and untreated, de novo and secondary mds of all french-american- british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia ) and intermediate- 1, intermediate- 2, and high-risk international prognostic scoring system groups.- dacogen is indicated for the treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary acute myeloid leukaemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy

জর্ডন - ইংরেজি - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية الشرق شخشير - orient drug store co - decitabine 50 milligram - 50 milligram